Publications by authors named "Thomas Siler"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

23,699

Total Likes

382

Extended Reach

232,939

Social Features

40
R
Reply to Gan , to Calzetta , and to Poor.
Antonio Anzueto, Igor Z Barjaktarevic, Thomas M Siler, Tara Rheault, Thomas Bengtsson

Am J Respir Crit Care Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.
Fernando J Martinez, Gerard J Criner, Christian Gessner, Margret Jandl, Fernando Scherbovsky, Thomas M Siler

Am J Respir Crit Care Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Samuel Bardsley, Gerard J Criner, David M G Halpin, MeiLan K Han, Nicola A Hanania, Thomas M Siler

Respir Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correct use and ease-of-use of placebo ELLIPTA dry-powder inhaler in adult patients with chronic obstructive pulmonary disease.
Thomas M Siler, Renu Jain, Kathryn Collison, Raj Sharma, Laura Sutton

PLoS One· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD.
Thomas M Siler, Claire Hohenwarter, Kuangnan Xiong, Kenneth Sciarappa, Shahin Sanjar

Pulm Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
Arnaud Bourdin, Gerard Criner, Gilles Devouassoux, Mark Dransfield, David M G Halpin, Thomas M Siler

Chronic Obstr Pulm Dis· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study.
Thomas M Siler, Edmund J Moran, Chris N Barnes, Glenn D Crater

Chronic Obstr Pulm Dis· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Edward M Kerwin, Thomas M Siler, Samir Arora, Patrick Darken, Earl Rose

Int J Chron Obstruct Pulmon Dis· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
Thomas M Siler, Alison C Donald, Dianne O'Dell, Alison Church, William A Fahy

Int J Chron Obstruct Pulmon Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
Fernando J Martinez, Klaus F Rabe, Gary T Ferguson, Leonardo M Fabbri, Stephen Rennard, Thomas M Siler

Chest· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Thomas M Siler, Atsushi Nagai, Catherine A Scott-Wilson, Dawn A Midwinter, Courtney Crim

Respir Med· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
Thomas M Siler, Edward Kerwin, Karen Singletary, Jean Brooks, Alison Church

COPD· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study.
Edward Kerwin, Thomas M Siler, Phillip Korenblat, Alexander White, Joerg H Eckert

Chronic Obstr Pulm Dis· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Thomas M Siler, Edward Kerwin, Ana R Sousa, Alison Donald, Rehan Ali

Respir Med· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect.
Thomas M Siler, Craig F LaForce, Farid Kianifard, James Williams, Selwyn Spangenthal

Int J Chron Obstruct Pulmon Dis· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
Eugene R Bleecker, Thomas Siler, Roger Owen, Benjamin Kramer

Int J Chron Obstruct Pulmon Dis· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.
Gregory Feldman, Thomas Siler, Niyati Prasad, Damon Jack, Simon Piggott

BMC Pulm Med· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease.
Stephen I Rennard, Charles Fogarty, Steven Kelsen, William Long, Joe Ramsdell, Thomas Siler

Am J Respir Crit Care Med· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis